Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,

Slides:

Advertisements

Similar presentations

Lab Experience with HIV RNA NAAT

Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Identifying HIV-2 Infections Using Differential Serological Assays HIV-1 (gp41)/HIV-2(gp36) (Select HIV or MultiSpot) by Testing HIV EIA Reactive Specimens.

IDENTIFICATION OF FACTORS IMPACTING THE DETERMINATION OF HIV INCIDENCE IN NON-RESEARCH-BASED, CLINICAL POPULATIONS Sill, A.M. 1 ; Constantine, N.T. 2 ;

Unit 6 Diagnosis & Follow-up of HIV Infection

Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.

Overview of Reverse Sequence Syphilis Testing u Presented May 2012 at Oregon Epidemiologist Conference by Doug Harger, Manager, STD Prevention and Control.

HIV Diagnostics and A New Testing Algorithm

6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.

Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

CDC HIV Diagnostics Conference December 5-7, 2007 Sensitivity of OraQuick and Early Generation Enzyme Immunoassay (EIA) within a Pooled HIV Nucleic Acid.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Acute HIV Infection: New Strategies for Detection

Testing algorithms used at Bureau of Labs Michigan Department of Community Health Information on testing algorithms for processing and reporting serological.

Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.

Alere TM HIV Combo Yuko Tamanoue, Product Development Department.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

OnSite TB/HIV Ab Rapid Test 2 in 1 test kit

HIV Testing CDC power point edited by M. Myers

Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.

HIV Diagnosis: New Tests, New Algorithms and a New Focus Berry Bennett, MPH Retrovirology Section Chief FL Bureau of Public Health Laboratories, FDOH

Screening for Acute HIV-1 Infection at NYC DOHMH Public Health Laboratory William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department.

Incorporation of the Aptima® HIV-1 RNA Assay into Serodiagnostic and Rapid Test Confirmation Testing Algorithms to Resolve Discordant Serological Results.

Results from the LA rapid testing study: What can they tell us about proposed point of care strategies? Kevin Delaney, MPH Division of HIV/AIDS Prevention.

Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa,

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,

Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.

CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.

Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.

Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.

Limitations of HIV Antibody Testing in a Population with High Incidence of HIV Infection Joanne Stekler 1,2, Paul D. Swenson 1,2, Robert W. Coombs 1, Joan.

HIV/AIDS is preventable and treatable, but is incurable.

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.

New HIV Test Algorithms and Revised Adult HIV Case Report Form (DCH #1355) HIV Surveillance HIV/STD/VH/TB Epidemiology Section Bureau of Epidemiology Michigan.

HIV diagnosis (general) ImmunoassaysNAT (PCR)

Background J Kuruc 1, A Mayo 1,L Sampson 2, J Barnhart 2,M Brinson 5,S McCoy 3,E Foust 2, R Ashby 2, C Pilcher 4, C Gay 1,P Leone 1,2 and J Eron 1 1 University.

In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,

1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.

Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System RITA as part of routine national HIV surveillance: Experience.

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,

HIV/AIDS is preventable and treatable, but is incurable.

Test 1Test 2Test 3Test 4Test 5Test 6 Sensitivity Specificity PPV NPV Performance.

Dengue fever caused by dengue virus (DENV), a member of Flaviviridae leads to large global disease burden. Detection of immunoglobulin M (IgM) and nucleic.

BioPlex 2200 HIV Ag-Ab Assay

RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.

Ricardo da Silva de Souza – August 2006 Rapid and Efficient Acute HIV Detection by 4th Generation Ag/Ab ELISA R. De Souza 1, C. Pilcher 2, S. Fiscus 2,

1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.

Evaluation of 5 different tests for Trichomonas vaginalis infection and cost effective planning for clinical implementation B. Nathan 1, J Appiah 2, D.

Copyright © 2010 American Medical Association. All rights reserved.

TUPEB018 Field evaluation of rapid HIV serologic tests for screening HIV-1/2 infection using serum samples from Rakai Cohort, Uganda. S.C. Kagulire, P.D.

California Clinical Laboratory Association

In the Footsteps of the WHO – Rapid HIV Testing in America

San Francisco Department of Public Health

INTEGRATING HIV AND HCV TESTING.

at Anonymous Clinic, The Thai Red Cross AIDS Research Centre

A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING

Presentation transcript:

Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David, M. Salfinger, M. Chan, D. Willis, S. Crowe, Florida Department of Health, Bureau of Laboratories-Jacksonville, FL., USA.

Objectives Primary: To assess clinical performance of each immunoassay for possible ITN purposes within our current algorithm, not specifically for a dual immunoassay algorithm design. Strategy-specific: Increase algorithm sensitivity w/o compromising specificity as compared to a traditional algorithm. Demonstrate potential reagent cost-effectiveness on seropositive results as compared to a traditional algorithm. Demonstrate improve testing TAT on non-seronegative reporting. Reduce the number of inconclusive reports.

Methods Assay selection; BioRad’s HIV-1/2 Plus O EIA Siemens Advia Enhanced HIV-1/O/2 n = 2,765 fresh serum samples tested by both 3 rd generation immunoassays. TP = 92 (3.3%), 90 WBlot +, 1 NAAT +, 1 subsequent seroconversion TN = 2,673

A1 = HIV1/2 immunoassay (e.g. EIA or CIA) n = 2765 TP = 92 (3.3%) A1 (+) BR1/2/O = 98 E1/2/O = 98 A1 (-) Negative for HIV-1 & HIV-2 antibodies BR1/2/O = 2667 E1/2/O = 2667 A2 = HIV 1/2 immunoassay in duplicate (e.g. EIA or CIA or non-waived rapid) A2 (++) (+-) Presumptive positive for HIV-1 or HIV-2 antibodies; requires medical follow-up for further evaluation and testing E1/2/O = 96 BR1/2/0 = 96 A1/A2 sensitivity = 100% PPV = 95.8% A1/A2 specificity = 99.85%NPV = 100% Inconclusive for HIV antibodies; request plasma redraw for NAAT *. Requires medical follow-up for further evaluation and testing. A2(- -) E1/2/O = 2 BR1/2/O = 2 A1 (- -) Repeat A1* *This study did not include the (duplicate) ? ? repeat AI pathway. A1 (++ or +-) HIV-2 testing; Strategy 5, if 1 or more of the following apply: 1) Indicated by clinical presentation 2) Indicated by local HIV-2 prevalence 3) Indicated by client/patient travel or risk history * If window period infection is suspected, refer to Acute HIV Infection Testing, Strategy 4. Strategy 3. HIV 1/2 Dual Immunoassay

Table 1 Individual Assay & Strategy Performance Assay(s) Clinical SensitivityClinical Specificity BioRad’s HIV-1/2 Plus O EIA 100% (92/92) 99.78%** (2667/2673) Siemens Advia HIV-1/O/2 CIA 100% (92/92) 99.78%** (2667/2673) BioRad/Siemens Dual Algorithm 100% (92/92) 99.85%** (2669/2673) Siemens/BioRad Dual Algorithm 100% (92/92) 99.85%** (2669/2673) HIV-1/2 Plus O EIA*/ HIV-1 Wblot Algorithm 97.8% (90/92) 100% (2673/2673) * Optional replacement with Advia HIV-1/O/2 w/ same performance. ** Based on Western Blot negative and/or limited seronegative follow up.

Table 2 Discordant Results Specimen HIV-1/2 Plus O Advia HIV-1/O/2 Western NAAT Follow up S/CO* Index* Blot (HIV-1) (Aptima HIV-1 RNA) no bandsnegativeseronegative no bandsnegativenone 31.13<0.05no bandsnegativenone not performednegativenone not performednegativenone no bandsnegativeseronegative p24 onlynot performedseronegative 81.62<0.05no bandsnot performedseronegative no bandspositiveseroconvert no bandsnegativeseroconvert no bandspositiveseroconvert no bandspositiveseroconvert no bandspositiveseroconvert no bandspositiveseroconvert * 1.0 s/co or index values are averages of replicates. Color representations; false positive screens, false negative blots, confirmed HIV-1 acute infections.

Conclusions Increased sensitivity over the reference method. Increased specificity over either 3 rd generation immunoassay in stand-alone use. Comparable specificity to a licensed HIV-1 WBlot, the licensed HIV-1 NAAT assay and several POC HIV-1/2 rapid devices. Did not demonstrate the ability to detect a very limited number of confirmed HIV-1 acute infections. Laboratory-TAT of seropositive results potentially could be reduced by 1-3 days. Diagnostic reagent costs could be reduced for non- negative specimens by 26-43%.

Table 3 Application Comparisons Strategy Turn-Around-Time (non-negatives)Reagent Costs 3 rd gen. EIA / Western Blot Algorithm ~3-4 days (laboratory time only)~$28.80 per non-negative result ($1.50 x 3 + $24.30) Dual Immunoassay Algorithm (EIA 1 st, CIA 2 nd ) ~1-2 days (laboratory time only)~$12.30 per non-negative result ($ $5.40 x 2) (based on 5 non- negatives/run) Dual Immunoassay Algorithm (EIA 1 st, CIA 2 nd ) ~2-3 days (laboratory time only)~$8.70 per non-negative result ($ $3.60 x 2) (based on 20 non- negatives/run) Dual Immunoassay Algorithm (CIA 1 st, EIA 2 nd ) ~2-3 days (laboratory time only)~$8.40 per non-negative result ($ $3.45 x 2) (based on 20 non- negatives/run)

Study Notes & Needs Need to expand study size & include more acute and early infections (focus on increasing specificity w/o compromising the improved sensitivity); - Better assay(s) selections? - The addition of a 3 rd assay? - The use of a S/CO threshold value to assist in further testing, referrals and/or reporting needs? Need for reproducibility data over more than one lot# per assay. Need for seroconversion panels (budgetary restraints in our case) Note: Based on this study’s limited number of AIs (4) and if AIT is desired, perhaps consider the Strategy 5 add-on. Note: Large automated analysis platforms are often required to accompany these newer diagnostic assays and possibly could impact the cost-effectiveness of a dual immunoassay algorithm. Use of other diagnostic applications (HBV, HCV, etc.) on the secondary platform may counter some of the additional costs. Note: The “Random access” feature of at least one immunoassay has the potential to decrease TAT in a dual immunoassay algorithm but the “control bracketing” requirement may lessen the appeal when testing small numbers of initial reactives.